 Paul Norman
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 56 | 2024 | 92 | 10.480 |
Why?
| | Killer Cells, Natural | 51 | 2024 | 382 | 7.520 |
Why?
| | Haplotypes | 38 | 2024 | 453 | 4.210 |
Why?
| | Alleles | 43 | 2024 | 791 | 3.790 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 32 | 3.760 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 174 | 3.740 |
Why?
| | HLA Antigens | 21 | 2024 | 224 | 3.380 |
Why?
| | HLA-C Antigens | 19 | 2024 | 33 | 3.220 |
Why?
| | Polymorphism, Genetic | 30 | 2024 | 612 | 2.690 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 16 | 2.410 |
Why?
| | HLA-B Antigens | 20 | 2024 | 56 | 2.290 |
Why?
| | Immunogenetics | 5 | 2024 | 6 | 2.220 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 18 | 2.200 |
Why?
| | Genotype | 32 | 2024 | 1774 | 2.170 |
Why?
| | Evolution, Molecular | 18 | 2022 | 437 | 1.900 |
Why?
| | Selection, Genetic | 12 | 2024 | 243 | 1.440 |
Why?
| | HLA-A Antigens | 11 | 2023 | 50 | 1.380 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.330 |
Why?
| | Genetic Variation | 17 | 2024 | 876 | 1.270 |
Why?
| | High-Throughput Nucleotide Sequencing | 13 | 2024 | 440 | 1.260 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 70 | 1.060 |
Why?
| | Receptors, Immunologic | 8 | 2021 | 201 | 1.020 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 6 | 0.910 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 165 | 0.870 |
Why?
| | Multimorbidity | 1 | 2023 | 34 | 0.860 |
Why?
| | Gene Frequency | 15 | 2024 | 481 | 0.850 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1197 | 0.820 |
Why?
| | Ligands | 14 | 2023 | 565 | 0.810 |
Why?
| | Herpesviridae | 1 | 2022 | 21 | 0.810 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.810 |
Why?
| | Humans | 113 | 2024 | 114757 | 0.780 |
Why?
| | Primates | 3 | 2019 | 111 | 0.780 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 689 | 0.770 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 138 | 0.760 |
Why?
| | Communicable Diseases | 1 | 2023 | 129 | 0.760 |
Why?
| | Genome, Human | 5 | 2017 | 351 | 0.720 |
Why?
| | Genetics, Population | 10 | 2021 | 188 | 0.680 |
Why?
| | Peptides | 4 | 2022 | 849 | 0.660 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 524 | 0.660 |
Why?
| | Major Histocompatibility Complex | 3 | 2024 | 219 | 0.640 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 353 | 0.640 |
Why?
| | Point Mutation | 3 | 2017 | 216 | 0.620 |
Why?
| | Heterozygote | 1 | 2019 | 251 | 0.610 |
Why?
| | Pan troglodytes | 9 | 2017 | 47 | 0.600 |
Why?
| | Protein Binding | 10 | 2019 | 1897 | 0.580 |
Why?
| | Complement C4 | 1 | 2017 | 25 | 0.570 |
Why?
| | Leukemia | 1 | 2019 | 210 | 0.560 |
Why?
| | Receptors, KIR2DL4 | 2 | 2016 | 3 | 0.550 |
Why?
| | Mucins | 1 | 2017 | 61 | 0.550 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 35 | 0.510 |
Why?
| | Exons | 1 | 2016 | 303 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 8 | 2024 | 2099 | 0.490 |
Why?
| | Population | 1 | 2014 | 28 | 0.470 |
Why?
| | Immunity, Innate | 7 | 2024 | 723 | 0.460 |
Why?
| | Polymorphism, Single Nucleotide | 11 | 2021 | 1892 | 0.460 |
Why?
| | Linkage Disequilibrium | 8 | 2017 | 245 | 0.450 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.450 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 8 | 0.440 |
Why?
| | Malaria | 1 | 2013 | 49 | 0.430 |
Why?
| | Cell Line | 8 | 2019 | 2639 | 0.430 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 118 | 0.420 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1233 | 0.400 |
Why?
| | T-Lymphocytes | 6 | 2024 | 1745 | 0.390 |
Why?
| | DNA Copy Number Variations | 3 | 2021 | 158 | 0.380 |
Why?
| | Cytomegalovirus | 3 | 2024 | 144 | 0.370 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2791 | 0.370 |
Why?
| | Behcet Syndrome | 2 | 2021 | 16 | 0.350 |
Why?
| | Biological Evolution | 5 | 2019 | 416 | 0.350 |
Why?
| | Minority Groups | 2 | 2024 | 227 | 0.350 |
Why?
| | Epitopes | 8 | 2019 | 435 | 0.340 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 1988 | 0.330 |
Why?
| | Antigens, CD | 5 | 2017 | 443 | 0.330 |
Why?
| | Immunoglobulins | 3 | 2023 | 143 | 0.330 |
Why?
| | Models, Molecular | 5 | 2019 | 1378 | 0.330 |
Why?
| | Meiosis | 1 | 2009 | 59 | 0.330 |
Why?
| | Recombination, Genetic | 2 | 2010 | 176 | 0.330 |
Why?
| | Genotyping Techniques | 3 | 2019 | 69 | 0.320 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 182 | 0.310 |
Why?
| | Phylogeny | 12 | 2017 | 794 | 0.310 |
Why?
| | China | 3 | 2024 | 162 | 0.290 |
Why?
| | Signal Transduction | 3 | 2019 | 4522 | 0.290 |
Why?
| | Oceania | 2 | 2024 | 3 | 0.290 |
Why?
| | Immune System | 2 | 2019 | 173 | 0.280 |
Why?
| | Multigene Family | 3 | 2018 | 193 | 0.270 |
Why?
| | Egypt | 2 | 2023 | 10 | 0.270 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 5 | 0.260 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 262 | 0.260 |
Why?
| | Genomics | 5 | 2021 | 639 | 0.260 |
Why?
| | Virus Activation | 2 | 2024 | 78 | 0.260 |
Why?
| | Codon | 2 | 2016 | 86 | 0.260 |
Why?
| | Animals | 26 | 2024 | 31762 | 0.260 |
Why?
| | Phenotype | 7 | 2024 | 2812 | 0.260 |
Why?
| | Thymus Gland | 2 | 2024 | 296 | 0.250 |
Why?
| | Sequence Analysis, DNA | 7 | 2018 | 728 | 0.250 |
Why?
| | Parkinson Disease | 2 | 2020 | 345 | 0.250 |
Why?
| | Hominidae | 2 | 2019 | 79 | 0.240 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 14 | 0.230 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 126 | 0.230 |
Why?
| | Female | 29 | 2024 | 59507 | 0.230 |
Why?
| | Australia | 1 | 2024 | 207 | 0.230 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 84 | 0.230 |
Why?
| | Quinolines | 1 | 2024 | 129 | 0.220 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 76 | 0.220 |
Why?
| | Male | 23 | 2024 | 55579 | 0.220 |
Why?
| | Immunity, Cellular | 1 | 2005 | 248 | 0.220 |
Why?
| | Gene Dosage | 3 | 2021 | 134 | 0.210 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 152 | 0.210 |
Why?
| | Leukocytes | 1 | 2004 | 277 | 0.210 |
Why?
| | Iran | 2 | 2020 | 36 | 0.210 |
Why?
| | Centromere | 2 | 2015 | 42 | 0.210 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1044 | 0.210 |
Why?
| | Sequence Alignment | 3 | 2021 | 325 | 0.200 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.200 |
Why?
| | Longevity | 1 | 2023 | 137 | 0.200 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 26 | 0.200 |
Why?
| | Health | 1 | 2022 | 74 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 309 | 0.190 |
Why?
| | Yersinia pestis | 1 | 2021 | 34 | 0.190 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 7 | 0.190 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 263 | 0.190 |
Why?
| | Plague | 1 | 2021 | 42 | 0.190 |
Why?
| | Malaysia | 1 | 2020 | 4 | 0.190 |
Why?
| | Pregnancy | 6 | 2020 | 5525 | 0.190 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 132 | 0.190 |
Why?
| | HLA-D Antigens | 1 | 2021 | 34 | 0.180 |
Why?
| | Psoriasis | 1 | 2021 | 74 | 0.180 |
Why?
| | Arabs | 1 | 2020 | 4 | 0.180 |
Why?
| | HLA-DRB1 Chains | 2 | 2019 | 98 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 664 | 0.170 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.170 |
Why?
| | B-Lymphocytes | 4 | 2017 | 769 | 0.170 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 2 | 0.170 |
Why?
| | Protozoan Infections | 1 | 2019 | 10 | 0.170 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 32 | 0.170 |
Why?
| | Telomere | 3 | 2014 | 202 | 0.160 |
Why?
| | Adult | 15 | 2024 | 30548 | 0.160 |
Why?
| | Indians, North American | 2 | 2015 | 570 | 0.160 |
Why?
| | Base Sequence | 3 | 2016 | 2118 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 618 | 0.160 |
Why?
| | Phylogeography | 1 | 2019 | 44 | 0.160 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 536 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 45 | 0.150 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 35 | 0.150 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 125 | 0.150 |
Why?
| | Indians, South American | 2 | 2009 | 22 | 0.150 |
Why?
| | Flow Cytometry | 7 | 2018 | 1086 | 0.150 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 8 | 0.150 |
Why?
| | Syk Kinase | 1 | 2017 | 18 | 0.150 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 503 | 0.150 |
Why?
| | Binding Sites | 6 | 2015 | 1176 | 0.150 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2321 | 0.140 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 79 | 0.140 |
Why?
| | Pan paniscus | 1 | 2017 | 5 | 0.140 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.140 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 26 | 0.140 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.140 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 797 | 0.140 |
Why?
| | Transplantation, Homologous | 4 | 2024 | 386 | 0.140 |
Why?
| | Women's Health | 1 | 2019 | 271 | 0.140 |
Why?
| | Virus Diseases | 1 | 2019 | 195 | 0.140 |
Why?
| | Models, Genetic | 4 | 2015 | 565 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 97 | 0.140 |
Why?
| | HIV-1 | 1 | 2022 | 768 | 0.140 |
Why?
| | Reference Standards | 1 | 2017 | 159 | 0.140 |
Why?
| | Open Reading Frames | 1 | 2017 | 116 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1361 | 0.140 |
Why?
| | Gene Flow | 2 | 2015 | 77 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 125 | 0.130 |
Why?
| | Molecular Typing | 1 | 2016 | 18 | 0.130 |
Why?
| | Case-Control Studies | 6 | 2024 | 3005 | 0.130 |
Why?
| | Placentation | 2 | 2016 | 40 | 0.130 |
Why?
| | Protein Conformation | 1 | 2019 | 811 | 0.130 |
Why?
| | Donor Selection | 1 | 2016 | 66 | 0.130 |
Why?
| | Gene Expression | 4 | 2018 | 1420 | 0.130 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 22 | 0.130 |
Why?
| | Sf9 Cells | 1 | 2015 | 9 | 0.130 |
Why?
| | Spodoptera | 1 | 2015 | 36 | 0.130 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2015 | 44 | 0.130 |
Why?
| | Baculoviridae | 1 | 2015 | 45 | 0.130 |
Why?
| | Human Migration | 1 | 2015 | 19 | 0.120 |
Why?
| | Insecta | 1 | 2015 | 65 | 0.120 |
Why?
| | Research Report | 1 | 2015 | 75 | 0.120 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 70 | 0.120 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 198 | 0.120 |
Why?
| | Polynesia | 1 | 2014 | 3 | 0.120 |
Why?
| | Biological Assay | 1 | 2015 | 113 | 0.120 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.120 |
Why?
| | New Zealand | 1 | 2014 | 41 | 0.120 |
Why?
| | Incidence | 1 | 2020 | 2312 | 0.120 |
Why?
| | Isoantibodies | 1 | 1995 | 57 | 0.120 |
Why?
| | Tissue Donors | 4 | 2024 | 317 | 0.120 |
Why?
| | Kidney Transplantation | 2 | 2003 | 541 | 0.120 |
Why?
| | DNA | 3 | 2021 | 1351 | 0.120 |
Why?
| | Glucose | 1 | 2019 | 897 | 0.120 |
Why?
| | Middle Aged | 12 | 2024 | 26757 | 0.110 |
Why?
| | Cell Differentiation | 4 | 2024 | 1699 | 0.110 |
Why?
| | Protein Folding | 1 | 2015 | 239 | 0.110 |
Why?
| | Mammals | 1 | 2015 | 245 | 0.110 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 22 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 345 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2011 | 218 | 0.110 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4409 | 0.110 |
Why?
| | Species Specificity | 4 | 2017 | 545 | 0.110 |
Why?
| | Metagenomics | 1 | 2014 | 131 | 0.110 |
Why?
| | Exome | 1 | 2014 | 200 | 0.110 |
Why?
| | Seals, Earless | 1 | 2012 | 3 | 0.110 |
Why?
| | Genetics, Medical | 3 | 2019 | 24 | 0.100 |
Why?
| | Hepatitis C | 1 | 2015 | 219 | 0.100 |
Why?
| | Saliva | 1 | 2014 | 189 | 0.100 |
Why?
| | Graft Survival | 1 | 1995 | 452 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 973 | 0.100 |
Why?
| | Polymerase Chain Reaction | 4 | 2017 | 994 | 0.100 |
Why?
| | Smoking | 1 | 2019 | 1384 | 0.100 |
Why?
| | CD56 Antigen | 2 | 2009 | 34 | 0.100 |
Why?
| | Environment | 1 | 2013 | 336 | 0.100 |
Why?
| | Graft Rejection | 1 | 1995 | 516 | 0.100 |
Why?
| | Software | 3 | 2024 | 536 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2017 | 722 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 78 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 1995 | 774 | 0.090 |
Why?
| | Organ Transplantation | 1 | 2013 | 159 | 0.090 |
Why?
| | Europe | 2 | 2021 | 336 | 0.090 |
Why?
| | North America | 2 | 2021 | 257 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2013 | 633 | 0.090 |
Why?
| | Gene Conversion | 1 | 2009 | 6 | 0.090 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 67 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 112 | 0.080 |
Why?
| | Africa | 3 | 2019 | 95 | 0.080 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 100 | 0.080 |
Why?
| | HIV Infections | 1 | 2022 | 2469 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2199 | 0.070 |
Why?
| | Child | 2 | 2019 | 18352 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 345 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 14 | 0.070 |
Why?
| | Receptors, Fc | 1 | 2007 | 45 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 353 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2007 | 167 | 0.070 |
Why?
| | Cohort Studies | 3 | 2021 | 4901 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2539 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2725 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 263 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 128 | 0.060 |
Why?
| | Algorithms | 2 | 2024 | 1468 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 136 | 0.060 |
Why?
| | HeLa Cells | 2 | 2015 | 562 | 0.060 |
Why?
| | Histocompatibility | 1 | 2003 | 26 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 385 | 0.060 |
Why?
| | United Kingdom | 1 | 2004 | 226 | 0.060 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 116 | 0.060 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.060 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 25 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 40 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 279 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 332 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 188 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 114 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 26 | 0.050 |
Why?
| | Young Adult | 3 | 2024 | 10463 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 39 | 0.050 |
Why?
| | DNA Primers | 2 | 2018 | 514 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 524 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2007 | 739 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 24 | 0.050 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 32 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 55 | 0.050 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 117 | 0.050 |
Why?
| | Homozygote | 1 | 2021 | 187 | 0.050 |
Why?
| | Aged | 5 | 2024 | 19094 | 0.050 |
Why?
| | Twins | 1 | 2001 | 240 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3350 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 594 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 233 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 264 | 0.040 |
Why?
| | Mice | 3 | 2024 | 14916 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2017 | 3890 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 47 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 31 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 51 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 53 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 795 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 489 | 0.040 |
Why?
| | Health Equity | 1 | 2019 | 53 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 936 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 180 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1002 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 384 | 0.040 |
Why?
| | Time Factors | 4 | 2006 | 6124 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 135 | 0.040 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 4 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 530 | 0.040 |
Why?
| | Butyrophilins | 1 | 2017 | 5 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2018 | 339 | 0.040 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 18 | 0.040 |
Why?
| | Lymphocyte Count | 3 | 2002 | 133 | 0.040 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 215 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 560 | 0.040 |
Why?
| | Gorilla gorilla | 1 | 2017 | 19 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 878 | 0.040 |
Why?
| | Liver | 1 | 2005 | 1631 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2019 | 201 | 0.040 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1270 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 130 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1843 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 372 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 72 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1350 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2024 | 6350 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 15 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 965 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Americas | 1 | 2015 | 19 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 73 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 195 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 40 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 48 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 156 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 357 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 596 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 206 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 283 | 0.030 |
Why?
| | United States | 2 | 2023 | 12176 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 187 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 4710 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 161 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 26 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 55 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 241 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 244 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 19 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 69 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1759 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 140 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 181 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 244 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 229 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 344 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1319 | 0.030 |
Why?
| | Demography | 1 | 2013 | 262 | 0.030 |
Why?
| | Feces | 1 | 2015 | 374 | 0.030 |
Why?
| | Ursidae | 1 | 2012 | 6 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 912 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 295 | 0.030 |
Why?
| | Cell Membrane | 1 | 2016 | 680 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 182 | 0.030 |
Why?
| | Genome | 1 | 2014 | 272 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2013 | 460 | 0.020 |
Why?
| | Diet | 1 | 2019 | 1080 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 307 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 921 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3416 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 334 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 313 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2011 | 3542 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 54 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 36 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 192 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1691 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 182 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 9089 | 0.020 |
Why?
| | Culture | 1 | 2011 | 124 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 211 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2196 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 52 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 8627 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1630 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 102 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 354 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 325 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 135 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2387 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 248 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 405 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 668 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 242 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 799 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 648 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 7 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4420 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 127 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 736 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 626 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2006 | 220 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 19 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2005 | 69 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 76 | 0.020 |
Why?
| | Microspheres | 1 | 2005 | 123 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 275 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 292 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1133 | 0.010 |
Why?
| | Asia | 1 | 2003 | 53 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1022 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 54 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 161 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 289 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 20 | 0.010 |
Why?
| | Utah | 1 | 2002 | 59 | 0.010 |
Why?
| | Cytokines | 1 | 2009 | 1843 | 0.010 |
Why?
| | Sex Factors | 1 | 2006 | 1717 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 270 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 494 | 0.010 |
Why?
| | Age Factors | 1 | 2006 | 2890 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 647 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1435 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 391 | 0.010 |
Why?
| | Adolescent | 2 | 2005 | 17808 | 0.010 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|